Neural Plasticity and Inflammatory Pain
项目来源
项目主持人
项目受资助机构
项目编号
立项年度
立项时间
研究期限
项目级别
受资助金额
学科
学科代码
基金类别
关键词
参与者
参与机构
1.Sense and Immunity: Context-Dependent Neuro-Immune Interplay
- 关键词:
- allergy and immunology; sensory neurons; asthma; inflammation;neuro-immunological signaling;GENE-RELATED PEPTIDE; VASOACTIVE-INTESTINAL-PEPTIDE; ALLERGIC AIRWAYINFLAMMATION; INNATE LYMPHOID-CELLS; CAPSAICIN NASAL CHALLENGE;SUBSTANCE-P; DENDRITIC CELL; EOSINOPHIL RECRUITMENT; TYPE-2 IMMUNITY;MAST-CELLS
The sensory nervous and immune systems, historically considered autonomous, actually work in concert to promote host defense and tissue homeostasis. These systems interact with each other through a common language of cell surface G protein-coupled receptors and receptor tyrosine kinases as well as cytokines, growth factors, and neuropeptides. While this bidirectional communication is adaptive in many settings, helping protect from danger, it can also become maladaptive and contribute to disease pathophysiology. The fundamental logic of how, where, and when sensory neurons and immune cells contribute to either health or disease remains, however, unclear. Our lab and others' have begun to explore how this neuro-immune reciprocal dialog contributes to physiological and pathological immune responses and sensory disorders. The cumulative results collected so far indicate that there is an important role for nociceptors (noxious stimulus detecting sensory neurons) in driving immune responses, but that this is highly context dependent. To illustrate this concept, we present our findings in a model of airway inflammation, in which nociceptors seem to have major involvement in type 2 but not type 1 adaptive immunity.
...2.Breaking barriers to novel analgesic drug development
- 关键词:
- MU-OPIOID RECEPTOR; CALCIUM-CHANNEL BLOCKER; II TYPE-2 RECEPTOR; ROOTGANGLION NEURONS; MECHANICAL PAIN HYPERSENSITIVITY; PERIPHERALNERVOUS-SYSTEM; PLACEBO-CONTROLLED TRIAL; CHRONIC CANCER PAIN;NEUROPATHIC PAIN; POTASSIUM CHANNELS
Acute and chronic pain complaints, although common, are generally poorly served by existing therapies. This unmet clinical need reflects a failure to develop novel classes of analgesics with superior efficacy, diminished adverse effects and a lower abuse liability than those currently available. Reasons for this include the heterogeneity of clinical pain conditions, the complexity and diversity of underlying pathophysiological mechanisms, and the unreliability of some preclinical pain models. However, recent advances in our understanding of the neurobiology of pain are beginning to offer opportunities for developing novel therapeutic strategies and revisiting existing targets, including modulating ion channels, enzymes and G-protein-coupled receptors.
...
